Both trials recruited patients with psoriatic arthritis who had not previously received biologic disease-modifying ...

Stagnant sales for Bristol Myers Squibb’s Sotyktu have raised questions about whether the tyrosine kinase 2 (TYK2) inhibitor ...

(RTTNews) - Drug maker Bristol-Myers Squibb Co. (BMY) Monday announced positive topline results from two pivotal Phase 3 trials evaluating Sotyktu (deucravacitinib) in adults with active psoriatic ...

Differences in how men and women manifest and experience psoriatic arthritis suggest it’s time to think of patient sex as a biomarker, one researcher said.

Long-term treatment with guselkumab is associated with sustained improvements in joint/skin symptoms and disease activity among patients with active PsA.

Bristol Myers on Monday said the two Phase 3 studies met their primary endpoint, with a significantly greater proportion of Sotyktu-treated patients achieving at least a 20% improvement in signs and ...

A research team from the University of Central Florida's College of Medicine conducted a study of patient perceptions of ...

Differences in how men and women manifest and experience psoriatic arthritis suggest it’s time to think of patient sex as a ...

The distinct radiographic features of psoriatic arthritis (PsA) help confirm it as a distinct entity from rheumatoid arthritis and highlight some unique non-synovial based disease imaging features.

Doctors say there are easy, inexpensive (or free!) arthritis self-care remedies that can make a world of difference. Odds are ...

30 Clearly, diagnosis and classification on symptoms alone are insufficient and some form of objective imaging ... good accuracy even without such key variables as psoriasis or rheumatoid factor. The ...